Between the first official report of outbreak in China & announcement of U.S. travel restrictions, 40,000+ travelers from China are estimated to have entered United States 3/
When Trump admin. expanded travel restrictions to Iran on 2/28 & to Europe on 3/12, it was too late
The US was approaching 2,000 cases, most likely a severe undercount
Chaotic implementation of ban on EU probably did more to spread virus than stop it 6/ politico.com/news/2020/03/1…
Scenario analysis suggests combination of travel restrictions within China and international travel restrictions against China may have delayed the spread of #COVID19
..those delays were more useful in nations such as New Zealand, Australia & Taiwan that used opportunity to expand testing, contact tracing and other aggressive measures to control spread of virus
In the past, @WHO has warned that travel bans are risky b/c give nations “a false impression of control” — a misperception that a ban would stop spread of disease
The experience of United States and others in this pandemic suggests WHO had a point 10/
The US has most outstanding, but that is misleading as President Biden just this week added 500m to US total pledged donation by 1.1B COVID vaccine doses
Maximizing potential benefit of vaccine donations depends on doses going where they can do the"most good" but there's no consensus on where that would be
This week's summit in Cornwall, UK should be the time when G7 leaders finally act on their promises to send surplus COVID-19 vaccine supplies to the many other countries where they remain scarce #G7UK
COVAX has been criticized by @ZekeEmanuel@GovindPersad & others for its population-based allocation scheme that does not direct most of its early vaccine supplies to the settings at the greatest risk of otherwise having high COVID-19 death rates 3/ nytimes.com/2021/05/24/opi…
Results published in Lancet indicate say this a/b 1 dose regimen
It will be interesting to see public response and distribution strategy for regimen w/lower efficacy than Pfizer/Moderna options & uncertainty about duration of protection thelancet.com/journals/lance…
Apparently, Oxford/AstraZeneca has not even filed a submission package with EMA yet. FDA decision isn't coming soon either.
This is such an important vaccine for global access and so much is strange about how its sponsors have pursued it reuters.com/article/us-hea…